VRTX is a good stock to have in one's portfolio based on its strong overall financial performance and robust pipeline progress.

Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.

Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.

GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.

GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

A bit of history Islamic finance during the time of the Prophet Muhammad was characterized by real transactions such as sale on credit and...

A bit of history Islamic finance during the time of the Prophet Muhammad was characterized by real transactions such as sale on credit and...

Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day.

AMD rides on strong portfolio, ZT and Silo acquisitions, and robust data center demand amid stiff competition from NVIDIA.